Pharmaceutical intermediates
Tegoprazan Intermediates
3 pharmaceutical intermediates for Tegoprazan. Indication: Gastroesophageal reflux disease; Helicobacter pylori infection; Duodenal ulcer.
About Tegoprazan
- Originator
- Pfizer Inc
- Indication
- Gastroesophageal reflux disease; Helicobacter pylori infection; Duodenal ulcer
- Approved Date
- 04/08/2022
Available intermediates
3 intermediates currently listed for Tegoprazan. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (R)-5,7-difluorochroman-4-ol | 1270294-05-7 | / | / |
| 1-benzyl-4-hydroxy-2-methyl-1H-benzo[d]imidazole-6-carboxylic acid | 1640981-19-6 | / | / |
| 7-hydroxy-N,N,2-triMethyl-3-tosyl-3H-benzo[d]iMidazole-5-carboxaMide | 942195-86-0 | / | / |
Building toward Tegoprazan?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →